{"id":"W2935807963","doi":"10.1634/theoncologist.2018-0695","title":"Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Hazard ratio; Lung cancer; Erlotinib Hydrochloride; Epidermal growth factor receptor; Oncology; Population; ERBB3; Cancer; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002943587,0.0001244137,0.0005319866,0.00008199707,0.00003789928,0.000005802278,0.00007384952,0.00005263312,0.00007579957],"category_scores_gemma":[0.00002882403,0.00006306831,0.00003722688,0.000280626,0.0001093844,0.00005272959,0.00001942217,0.0001283088,0.000001877207],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003289227,"about_ca_system_score_gemma":0.0004476306,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001638032,"about_ca_topic_score_gemma":0.0008304395,"domain_scores_codex":[0.9991131,0.0001031163,0.0002834903,0.0001675354,0.0001774209,0.0001553718],"domain_scores_gemma":[0.9992712,0.0001426951,0.0002306353,0.0002018491,0.0001227757,0.00003085003],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8758326,0.005738535,0.1143785,0.00008334438,0.0001586174,0.000007837846,0.002092161,0.0003606227,0.00005559548,0.00006156745,0.000105464,0.001125183],"study_design_scores_gemma":[0.9611226,0.01030852,0.02689547,0.0002097995,0.0004053306,4.869393e-7,0.000175226,0.0004913424,0.0001933295,0.0000132706,0.0000990982,0.0000855199],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9903402,0.00007800538,0.00001442367,0.0004717998,0.0001992233,0.005237244,0.00001145151,0.00001141812,0.003636254],"genre_scores_gemma":[0.9982371,0.00003701756,0.000137659,0.00009953509,0.00002247035,0.0002616941,0.0000745957,0.000015017,0.001114883],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08748303,"threshold_uncertainty_score":0.2571851,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01157483162358094,"score_gpt":0.3207546105925388,"score_spread":0.3091797789689579,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}